Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02657122 · ClinicalTrials.gov registry record · Phase 1
SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects
A Phase 1 study, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT02657122 is a Phase 1 study that has completed, run by Theravance Biopharma. The registered enrollment target is 72 participants.
The verdict
NCT02657122, a Phase 1 study, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses of the investigational drug TD-1473 compared to placebo in healthy subjects.
Interventions
- DRUG TD-1473 for SAD
- DRUG Placebo for SAD
- DRUG TD-1473 for MAD
- DRUG Placebo for MAD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02657122
The ClinicalTrials.gov registry entry for NCT02657122 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which TD-1473 for SAD is the first listed.
NCT02657122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02657122 about?
NCT02657122 is a clinical study titled "SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses of the investigational drug TD-1473 compared to placebo in healthy subjects.
What is the current status of trial NCT02657122?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2015-12. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02657122?
The interventions under investigation include: TD-1473 for SAD (DRUG), Placebo for SAD (DRUG), TD-1473 for MAD (DRUG), Placebo for MAD (DRUG).
Who is sponsoring clinical trial NCT02657122?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.